Literature DB >> 29022407

The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.

Paul Jedlicka1.   

Abstract

Entities:  

Keywords:  Ewing Sarcoma; Jumonji; KDM3A; cancer; demethylase; epigenetics

Mesh：

Substances：

Year:  2017        PMID： 29022407      PMCID： PMC5766342          DOI： 10.1080/14728222.2017.1391791

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


× No keyword cloud information.
  17 in total

Review 1.  Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.

Authors:  Jun Qi
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-12-01       Impact factor: 10.005

Review 2.  Advances in the development of histone lysine demethylase inhibitors.

Authors:  Tamara Maes; Elena Carceller; Jordi Salas; Alberto Ortega; Carlos Buesa
Journal:  Curr Opin Pharmacol       Date:  2015-06-05       Impact factor: 5.547

3.  The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Authors:  Aashi Chaturvedi; Laura M Hoffman; Alana L Welm; Stephen L Lessnick; Mary C Beckerle
Journal:  Genes Cancer       Date:  2012-02

4.  Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.

Authors:  T Nakatsuka; K Tateishi; Y Kudo; K Yamamoto; H Nakagawa; H Fujiwara; R Takahashi; K Miyabayashi; Y Asaoka; Y Tanaka; H Ijichi; Y Hirata; M Otsuka; M Kato; J Sakai; M Tachibana; H Aburatani; Y Shinkai; K Koike
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

5.  Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.

Authors:  Mamoru Uemura; Hirofumi Yamamoto; Ichiro Takemasa; Koshi Mimori; Hideyuki Hemmi; Tsunekazu Mizushima; Masataka Ikeda; Mitsugu Sekimoto; Nariaki Matsuura; Yuichiro Doki; Masaki Mori
Journal:  Clin Cancer Res       Date:  2010-09-07       Impact factor: 12.531

6.  The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.

Authors:  J K Parrish; M Sechler; R A Winn; P Jedlicka
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

Review 7.  Epigenetic changes in pediatric solid tumors: promising new targets.

Authors:  Elizabeth R Lawlor; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

8.  The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.

Authors:  M Sechler; J K Parrish; D K Birks; P Jedlicka
Journal:  Oncogene       Date:  2017-03-20       Impact factor: 9.867

9.  Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells.

Authors:  G-A Franzetti; K Laud-Duval; W van der Ent; A Brisac; M Irondelle; S Aubert; U Dirksen; C Bouvier; G de Pinieux; E Snaar-Jagalska; P Chavrier; O Delattre
Journal:  Oncogene       Date:  2017-01-30       Impact factor: 9.867

Review 10.  Histone demethylase JHDM2A is involved in male infertility and obesity.

Authors:  Yuki Okada; Keisuke Tateishi; Yi Zhang
Journal:  J Androl       Date:  2009-10-29
View more
  3 in total

Review 1.  Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.

Authors:  Mingli Li; Chun-Wei Chen
Journal:  Biomedicines       Date:  2022-06-05

2.  KDM3A-mediated SP1 activates PFKFB4 transcription to promote aerobic glycolysis in osteosarcoma and augment tumor development.

Authors:  Wei Wang; Bin Wang
Journal:  BMC Cancer       Date:  2022-05-19       Impact factor: 4.638

3.  KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.

Authors:  Lays Martin Sobral; Marybeth Sechler; Janet K Parrish; Tyler S McCann; Kenneth L Jones; Joshua C Black; Paul Jedlicka
Journal:  Genes Cancer       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.